Canada markets closed

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
134.21-8.51 (-5.96%)
At close: 04:03PM EDT
134.45 +0.24 (+0.18%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close142.72
Open142.20
Bid134.20 x 900
Ask135.42 x 1000
Day's Range134.09 - 142.32
52 Week Range106.86 - 175.91
Volume14,912,403
Avg. Volume5,507,111
Market Cap237.297B
Beta (5Y Monthly)0.69
PE Ratio (TTM)18.98
EPS (TTM)7.07
Earnings DateOct 27, 2022 - Oct 31, 2022
Forward Dividend & Yield5.64 (4.20%)
Ex-Dividend DateOct 13, 2022
1y Target Est158.85
  • Motley Fool

    Here's Why This Dividend King Is a Buy

    Among the most notable stocks to do so, AbbVie (NYSE: ABBV) is actually trading up 6% on the year. AbbVie is best known as the maker of the top-selling drug in the world, Humira. This stacked lineup of products explains how the drugmaker's net revenue increased 4.5% year over year to $14.6 billion in the second quarter.

  • Motley Fool

    Where Will AbbVie Be in 3 Years?

    In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year. Its other immunology drugs and the neuroscience business also are thriving.

  • Simply Wall St.

    AbbVie Inc. (NYSE:ABBV) is a favorite amongst institutional investors who own 70%

    To get a sense of who is truly in control of AbbVie Inc. ( NYSE:ABBV ), it is important to understand the ownership...